---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012000"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:08:47.169208+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lipocine's LPCN 1148 for cirrhosis highlighted in Hepatology journal

## Summary
- LPCN 1148 for men with cirrhosis featured in 'Hepatology Highlights' in June 2025 edition of Hepatology.
- Article contributed by Dr. Kevin Harris of Mayo Clinic; Phase 2 results published in same issue.
- FDA granted fast track designation for LPCN 1148 as treatment for sarcopenia in decompensated cirrhosis.
- CEO Mahesh Patel highlighted growing recognition of LPCN 1148's potential to improve cirrhosis outcomes.
- Company is exploring partnering opportunities for LPCN 1148.

## SEC filing metadata
- accession: 0001641172-25-012000
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225012000/0001641172-25-012000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225012000/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012000
- JSON: https://secwatch.observer/filing/0001641172-25-012000.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.